Literature DB >> 25199623

Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.

Chenfei Zhou1, Jun Ji1, Min Shi1, Liu Yang1, Yingyan Yu1, Bingya Liu1, Zhenggang Zhu1, Jun Zhang1.   

Abstract

Oxaliplatin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), also known as vorinostat, are potent antitumor agents. The aim of this study was to investigate the effect of SAHA on the antitumor efficacy of oxaliplatin in gastric cancer and the interaction between oxaliplatin and SAHA. Cell growth inhibition was evaluated using Cell Counting Kit‑8 and colony formation assays. Xenografts established in nude mice were used to assess tumor growth in vivo. Western blot analysis was used to detect the expression of acetyl‑histone H3, phosphorylated histone H2AX (γH2AX), B‑cell lymphoma 2 (Bcl‑2), cleaved caspase‑3, cleaved poly (ADP‑ribose) polymerase (PARP), phosphorylated- (p-)Src, Src, Akt and p‑Akt in gastric cancer cells. The in vitro growth of SGC‑7901, Hs746T and MKN28 gastric cancer cells was found to be dose‑dependently inhibited by oxaliplatin and SAHA. Furthermore, combined treatment was observed to be more effective in inhibiting cancer cell growth and colony formation than monotherapy. Similar effects were found in the xenografts. A positive interaction was identified between oxaliplatin and SAHA (between‑subject effects of oxaliplatin and SAHA, P<0.001). In addition, combined exposure to oxaliplatin and SAHA increased γH2AX expression and decreased Bcl‑2 expression. The expression of cleaved caspase‑3 and PARP was also increased with combination treatment. Oxaliplatin‑induced Src phosphorylation was detected in gastric cancer cells, as we have previously reported. However, this effect was inhibited by SAHA. The oxaliplatin‑induced Src phosphorylation was not impaired with Akt inhibition. In conclusion, oxaliplatin and SAHA exhibited a positive interaction when used in combination and were found to suppress gastric cancer cell survival and growth. The reversal of oxaliplatin‑induced Src activation may be responsible for this positive interaction.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25199623     DOI: 10.3892/mmr.2014.2548

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.

Authors:  M A Rochat; E Schlaepfer; R F Speck
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

2.  Epigenetic actions of environmental factors and promising drugs for cancer therapy.

Authors:  Zhong-Tian Bai; Bing Bai; Jun Zhu; Cui-Xia Di; Xun Li; Wen-Ce Zhou
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

3.  Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.

Authors:  Bin-Yong Liang; Min Xiong; Gui-Bao Ji; Er-Lei Zhang; Zun-Yi Zhang; Ke-Shuai Dong; Xiao-Ping Chen; Zhi-Yong Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

4.  Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.

Authors:  Bo Liao; Yingying Zhang; Quan Sun; Ping Jiang
Journal:  Cancer Med       Date:  2017-12-13       Impact factor: 4.452

Review 5.  Microbiota and epigenetics: promising therapeutic approaches?

Authors:  Amr El-Sayed; Mohamed Kamel; Lotfi Aleya
Journal:  Environ Sci Pollut Res Int       Date:  2021-07-28       Impact factor: 4.223

6.  The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.

Authors:  Hang Lu; Xue-Feng Yang; Xiao-Qing Tian; Shou-Long Tang; Lian-Qian Li; Shuang Zhao; Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2016-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.